Gsk (GSK) Amortizatization of Intangibles (2011 - 2013)
Gsk (GSK) recorded quarterly Amortizatization of Intangibles of $50.2 million in Q4 2013, up 0.82% quarter-over-quarter from $49.8 million in Q4 2012, and up 0.82% on a YoY basis from $49.8 million in Q4 2012.
Gsk (GSK) Amortizatization of Intangibles (2011 - 2013) Analysis & Trends
Gsk's Amortizatization of Intangibles history runs 3 years deep, the most recent figure standing at $50.2 million for Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 1.70 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | 931.00 Mn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 596.00 Mn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 50.19 Mn |
| Dec 31, 2013 | 50.19 Mn |
| Dec 31, 2012 | 49.78 Mn |
| Dec 31, 2012 | 49.78 Mn |
| Dec 31, 2011 | 50.29 Mn |
| Dec 31, 2011 | 50.29 Mn |